# Table of Contents

## State-of-the-Art in the Management of Cancer

### Prostate Cancer — Part I

#### Epidemiology

- Prostate Anatomy, Histology and Cancer Pathology
- Etiology and Pathogenesis
  - Genetic Factors
  - Growth Factors
- Screening and Chemoprevention
  - Screening Using PSA
  - Chemoprevention
- Diagnosis
  - Prostate Specific Antigen (PSA)
  - Other Biomarkers
  - AntiCancer
  - Cytogen
  - DIANON Systems
  - Horus Therapeutics
  - Matritech
  - Oncor
- Biopsy
- Radionuclide Bone Scans
- Radiimmuneocontigraphy
- Other Diagnostic Tests
- Optical Imaging

#### Prognosis

#### Treatment of Prostate Cancer

- Treatment of Localized Prostate Cancer
  - Radical prostatectomy
  - Neoadjuvant hormonal ablative therapy
  - External beam radiation therapy
- Brachytherapy
- Cryotherapy
- Hyperthermia
- Photodynamic therapy
- Fast neutron therapy
- Boron neutron capture therapy

### Current Therapeutic Approaches for Locally Advanced and Late-Stage Prostate Cancer

#### Treatment of Locally Advanced Prostate Cancer

#### Schering-Plough

#### Treatment of Metastatic Prostate Cancer

#### Treatment of Recurrent and Hormone-Refractory Prostate Cancer

#### ImmuneX

#### Other Drugs

### Adjunct and Combination Therapies

#### Adjunct Therapy Post Surgery/Radiotherapy

#### Chemotherapy and Combination and Multimodality Therapies in Advanced Disease

### Bone Pain Palliation

#### Amersham International

#### Mallinckrodt

#### Cytogen

#### Diatide

### Novel Drugs in Development

#### Identification of Genes Implicated in Prostate Cancer

#### Centocor

#### Genetech

#### LXR Biotechnology

#### Millennium Pharmaceuticals

#### Sequana Therapeutics

#### Tissue-Targeted Toxic Therapy

#### Immunotherapy/Vaccines

#### Apteon

#### Avigen

#### CEL-SCI

#### Cellcor

#### Cytel

#### Medarex

#### Jenner Technologies

#### Proteus Molecular Design

#### Somatix Therapy

#### Therion Biologics

#### United Biomedical

#### Immunotoxins

#### Prizm Pharmaceuticals

#### Natural Products

#### Carrington Laboratories

#### Paraceylan

#### University of Wisconsin

#### Other Drug Therapies

### Treatment of Metastatic Prostate Cancer

### Treatment of Recurrent and Hormone-Refractory Prostate Cancer

### ImmuneX

### Parke-Davis

### British Biotech

### Adjunct and Combination Therapies

### Adjuvant Therapy Post Surgery/Radiotherapy

### Chemotherapy and Combination and Multimodality Therapies in Advanced Disease

### Bone Pain Palliation

### Amersham International

### Mallinckrodt

### Cytogen

### Diatide

### Novel Drugs in Development

### Identification of Genes Implicated in Prostate Cancer

### Centocor

### Genetech

### LXR Biotechnology

### Millennium Pharmaceuticals

### Sequana Therapeutics

### Tissue-Targeted Toxic Therapy

### Immunotherapy/Vaccines

### Apteon

### Avigen

### CEL-SCI

### Cellcor

### Cytel

### Medarex

### Jenner Technologies

### Proteus Molecular Design

### Somatix Therapy

### Therion Biologics

### United Biomedical

### Immunotoxins

### Prizm Pharmaceuticals

### Natural Products

### Carrington Laboratories

### Paraceylan

### University of Wisconsin

### Other Drug Therapies

### Treatment of Metastatic Prostate Cancer

### Treatment of Recurrent and Hormone-Refractory Prostate Cancer

### ImmuneX

### Parke-Davis

### British Biotech

### Adjunct and Combination Therapies

### Adjuvant Therapy Post Surgery/Radiotherapy

### Chemotherapy and Combination and Multimodality Therapies in Advanced Disease

### Bone Pain Palliation

### Amersham International

### Mallinckrodt

### Cytogen

### Diatide

### Novel Drugs in Development

### Identification of Genes Implicated in Prostate Cancer

### Centocor

### Genetech

### LXR Biotechnology

### Millennium Pharmaceuticals

### Sequana Therapeutics

### Tissue-Targeted Toxic Therapy

### Immunotherapy/Vaccines

### Apteon

### Avigen

### CEL-SCI

### Cellcor

### Cytel

### Medarex

### Jenner Technologies

### Proteus Molecular Design

### Somatix Therapy

### Therion Biologics

### United Biomedical

### Immunotoxins

### Prizm Pharmaceuticals

### Natural Products

### Carrington Laboratories

### Paraceylan

### University of Wisconsin

### Other Drug Therapies

### Treatment of Metastatic Prostate Cancer

### Treatment of Recurrent and Hormone-Refractory Prostate Cancer

### ImmuneX

### Parke-Davis

### British Biotech

### Adjunct and Combination Therapies

### Adjuvant Therapy Post Surgery/Radiotherapy

### Chemotherapy and Combination and Multimodality Therapies in Advanced Disease

### Bone Pain Palliation

### Amersham International

### Mallinckrodt

### Cytogen

### Diatide

### Novel Drugs in Development

### Identification of Genes Implicated in Prostate Cancer

### Centocor

### Genetech

### LXR Biotechnology

### Millennium Pharmaceuticals

### Sequana Therapeutics

### Tissue-Targeted Toxic Therapy

### Immunotherapy/Vaccines

### Apteon

### Avigen

### CEL-SCI

### Cellcor

### Cytel

### Medarex

### Jenner Technologies

### Proteus Molecular Design

### Somatix Therapy

### Therion Biologics

### United Biomedical

### Immunotoxins

### Prizm Pharmaceuticals

### Natural Products

### Carrington Laboratories

### Paraceylan

### University of Wisconsin

### Other Drug Therapies

### Treatment of Metastatic Prostate Cancer

### Treatment of Recurrent and Hormone-Refractory Prostate Cancer

### ImmuneX

### Parke-Davis

### British Biotech

### Adjunct and Combination Therapies

### Adjuvant Therapy Post Surgery/Radiotherapy

### Chemotherapy and Combination and Multimodality Therapies in Advanced Disease

### Bone Pain Palliation

### Amersham International

### Mallinckrodt

### Cytogen

### Diatide

### Novel Drugs in Development

### Identification of Genes Implicated in Prostate Cancer

### Centocor

### Genetech

### LXR Biotechnology

### Millennium Pharmaceuticals

### Sequana Therapeutics

### Tissue-Targeted Toxic Therapy

### Immunotherapy/Vaccines

### Apteon

### Avigen

### CEL-SCI

### Cellcor

### Cytel

### Medarex

### Jenner Technologies

### Proteus Molecular Design

### Somatix Therapy

### Therion Biologics

### United Biomedical

### Immunotoxins

### Prizm Pharmaceuticals

### Natural Products

### Carrington Laboratories

### Paraceylan

### University of Wisconsin

### Other Drug Therapies
IN VITRO CURRENT METHODOLOGIES
GENETIC SUSCEPTIBILITY SCREENING
BREAST CANCER — PART II ASYMPTOMATIC POPULATION SCREENING AND SUSCEPTIBILITY TESTING
BREAST SELF EXAMINATION
Inventive Products
BREAST CANCER SCREENING BASED ON Mammography
Mammography Screening for Women Aged 40-49 Years
Problems Associated with Mammography
Mammography Screening Costs
GENETIC SUSCEPTIBILITY SCREENING
Susceptibility Screening in Breast Cancer
Myriad Genetics
OncoMed
Visible Genetics
BREAST CANCER — PART III DIAGNOSIS, STAGING, MONITORING AND PROGNOSIS
Current Methodologies
Tumor Differentiation
Proliferative Rate
Neopharm
Tumor Invasiveness or Metastatic Potential
Other Breast Cancer Markers
Inherited susceptibility
Estrogen- and progesterone-receptor proteins
p53
HER-2/neu (c-erbB-2)
Prostate-specific antigen (PSA)
Other markers/indicators
In vitro Testing Methodologies
In vitro Diagnostics
Biomira Diagnostics
Centocor
Geron
Horus Therapeutics
Matritech
Novopharm Biotech
Oncogene Science
Onco
cParacelsian
Reference Laboratory Services
Impath
MRDx Diagnostics
In vivo Imaging Approaches
Mammography
Digital mammography
Ultrasound Imaging
ATL
Mammoscintigraphy/Immunoscintigraphy
Antisoma
Biomira
Immunomedics
Targon
Magnetic Resonance Imaging (MRI)
Fonar
Positron Emission Tomography (PET)
Optical/Laser Imaging
Invasive Procedures
Biopsy
Biopsys Medical
United States Surgical
Ductoscopy
Intra-operative Cancer Detection
Neoprobe
More on Prostate Cancer
Novel Therapeutics
Gene Therapy
Axis Genetics
Calydon
Genome Therapeutics
Genta
Ingenex
Introgen Therapeutics
Immunotherapy
Centocor
Maxim Pharmaceuticals
Medarex
Other Developments
Genomics
Recommendations/Approvals
Hoechst Marion Roussel
Immunex
Schering-Plough
Breast Tumor Histology
Staging by Hormonal Status
Surgery
Standard Surgical Interventions
Mastectomy
Lumpectomy
Novel Surgical Approaches
Interstitial laser photoagulation
Cryosurgery
Ultrasound
Radiation Therapy
Adjuvant, Neoadjuvant, Salvage and Palliative Treatment Approaches
Hormonal Therapy
Antiestrogen Agents
Tamoxifen
Toremifene
Aromatase Inhibitors
Standard Cytotoxic Chemotherapy
Anthracyclines
Taxanes
High-dose (Density) Chemotherapy (HDC)
HDC with Hematopoietic Growth Factor Support
HDC with Hematopoietic Cell Transplantation
Autologous bone marrow transplantation
Peripheral blood stem cell transplantation
Treatment of Complications of Breast Cancer
Hypercalcemia/Bone Pain Palliation
Pamidronate
Breast Cancer — Part V Novel Drugs in Development
New Hormonal Therapies
Non-steroidal Anti-estrogens
Toremifene
Droloxifene
Iodoxifene
Raloxifene
Steroidal (Pure) Anti-estrogens
ICI 182, 780
Anti-progestins
Mifepristone
RTI-3021-020
LG2527 and LG2716
Aromatase Inhibitors
Exemestane
Luteinizing Hormone-releasing Hormone (LHRH) Agonists
Other Developments
D3967
Gęp3967
Fluasterone
Growth Factor Modulation
ONCOLOGY KNOWLEDGEbase and ONCOLOGY DRUGS DATABASE

NEW MEDICINE has designed and plans to maintain an in-depth information capability in the oncology field. This body of knowledge incorporates data from every aspect of oncology and is organized to give the user maximum flexibility in viewing data by category.

In the ONCOLOGY DRUGS Database agents are listed by generic and brand name and number, by developer and affiliate (including a detailed description of the type of affiliation), by various other criteria (drug type, drug class, etc.), by mechanism, technology and indication. Also, the database identifies the targets of the agents in development and the indication. The status of each agent is listed by indication and a preclinical and clinical history is presented by indication, where appropriate. A hard copy version of the ONCOLOGY DRUGS Database is expected to be released by the middle of September 1997. In the meantime, our first product, a report on cancer vaccines (see blurb on page 6) is being released in June 1997.

The ONCOLOGY KNOWLEDGEbase, which is still under development, when completed, will incorporate information on all aspects of oncology, including new drugs in development (described above), detailed descriptions of mechanisms of malignancy, anti-cancer drug targets and types, technologies, indications (including extensive epidemiology and current therapy) and profiles of companies and academic institutions involved in this area, as well as delivery of services. Information is being gleaned from a variety of sources, including company releases, journal articles, meeting attendance, review of abstracts and personal communications. The ONCOLOGY KNOWLEDGEbase is expected to be formally released in early 1998 and maintained by NEW MEDICINE on an ongoing basis. To request a sample entry from this database, please use the order form on page eleven of this brochure.
### Gene-modified tumor cell vaccines
- Targeting Drugs to the Vascular Endothelium
- Targeted Delivery of Cisplatin

### Prostate Cancer Staging
- Biochemical Markers
- Other in vitro Staging Approaches
- In vivo Imaging
- High-resolution magnetic resonance imaging (MRI)
- Positron emission tomography (PET)
- Immunoscintigraphy

### Opportunistic Infections in Cancer Patients
From the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, LA, September 15-18, 1996

- **Bacterial Vaginosis, Cervicitis, Human Papillomavirus (HPV) and CIN**
- **Other Bacterial Infections**
  - Vancomycin-resistant Enterococci (VRE)
  - Emerging Resistance to Staphylococcus Epidermidis
  - Stentrotrophomonas maltophilia
  - New Therapeutic Modalities for Opportunistic Bacterial Infections
  - Quinupristin/dalfopristin
  - Ceftirome
  - Analysis of Cost-effective Bacterial Prophylaxis

### Viral Infections
- Penciclovir for Cold Sores
- Ganciclovir for Prevention of Cytomegalovirus (CMV) Disease

### Fungal Infections
- Empirical Fluconazole in Febrile Neutropenic Patients
- Itraconazole for Antifungal Prophylaxis
- Amphotericin B in Intralipid for Candidemia

### Management of Breast Cancer
From the 19th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 12-14, 1996

- **New Approaches in High Dose Chemotherapy for the Treatment of Breast Cancer**

### TOPoisomerase I Inhibitors
From the 21st Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, November 1-5, 1996

- Irinotecan
  - Colorectal Cancer
  - Monotherapy as second-line therapy
  - Combination therapy
  - First-line combination therapy
  - Lymphoma

### Topotecan
- Ovarian Cancer
- Small Cell Lung Cancer
- Metastatic Brain Cancer

### Technology Update

#### Cancer Vaccines — Humoral Versus Cellular Immunity

- **Rationale for Cancer Vaccine Development**
- **Human Immune Response**
- **Vaccines Eliciting a Humoral (B Cell) Immune Response**
  - Active Specific Immunotherapy (ASI)
  - Biomira
  - ImmunoTherapy Corporation
  - Progenics Pharmaceuticals
  - Stentor Pharmaceuticals
  - Somatix Therapy
  - Ribi ImmunoChem Research
  - Vical

#### Vaccines Eliciting a Cellular (T Cell) Immune Response
  - Tumor Antigen Vaccines
  - Cyte
  - Lidak Pharmaceuticals
  - Heat Shock Proteins
  - Antigenics
  - StressGen Biotechnologies
  - Adaptive (Cellular) Immunotherapy

#### Cancer Vaccines That Stimulate Both Humoral and Cell-Mediated Immunity
- Allogeneic Tumor Cell Vaccines
- Ribi ImmunoChem Research
- Gene Transfer Into Tumor Cells
- Somatix Therapy
- Therion Biologics
- Vical

#### Potential Markets for Cancer Vaccines
RANDOMIZED CLINICAL TRIALS IN ONCOLOGY

WHAT ARE ONCOLOGY RCTS? 370

RCT PATIENT SELECTION AND RANDOMIZATION APPROACHES 371

Patient Selection 371
Statistical Considerations 371

THE IMPACT OF RCTS IN ONCOLOGY 372

Use of RCTs in Oncology is Expected to Intensify 373

TYPES OF RCTS IN ONCOLOGY 373

RCTs in Cancer Prevention 373
RCTs to Evaluate Screening and Diagnostic Approaches 374
Role of RCTs in Evaluating Treatment Modalities 374
RCTs in primary therapies 374
RCTs in adjuvant therapies 374
RCTs in neo-adjuvant therapies 374
RCTs in Advanced Disease 374
RCTs in Supportive Care 374
New Therapeutic Technologies and RCTs 374

SURROGATE ENDPOINTS 374

CHALLENGES IN INTERPRETING RCTS 376

GENERATING ACTIONABLE INFORMATION FROM RCTS 376

Clinical Meaning of RCT Results 376

CURRENT CHALLENGES IN CONDUCTING RCTs 377

Costs 377
Ethical Considerations 377
Other Limiting Factors 377

RCT ALTERNATIVES 377

Large, Simplified RCTs (LSRCTs) 378
Meta-Analysis 378
Health Economic Models 379
Monte Carlo Simulations 379

ANTI-CANCER DRUG DEVELOPMENT

TOPOISOMERASE I INHIBITORS

Camptothecin Analogs 528
Mechanism of Action 528
Drug Resistance 529
Toxicity 529

COMMERCIALY AVAILABLE TOPO I INHIBITORS 529

Irinotecan (CPT-11) 530
Colorectal cancer 531
Lung cancer 531
Hematologic malignancies 532
CNS cancer 532
Other cancers 532
Topotecan 532

Ovarian cancer 534
Hematologic malignancies 534
Progressive high grade gliomas 537
Other cancers 539

NOVEL CAMPTOTHECIN ANALOGS/DERIVATIVES 539

9-Aminocamptothecin 539
GI 147211 539
Karencetics 539

NOVEL TOPOISOMERASE I INHIBITORS 540

Flavonoids 540
NU/CRF 505 540
NB-506 540
NSC 314662 540
Pyrazoloacridine 541

TAS-103 541
Other Agents 541
Mono-, bi- and terbenzimidazoles 541
Intepolcine 541
Protoberberine alkaloids 541
Morpholinyl analogs of doxorubicin 542

CORRECTIONS, ADDITIONS AND AMPLIFICATIONS

Corrections 447
Introgen Therapeutics 447
Additions 447
More on Prostate Cancer 447
Bone Care International 447

CANCER VACCINES: TECHNOLOGY, PRODUCTS, MARKETS AND BUSINESS OPPORTUNITIES

REPORT #401 250 PAGES JUNE 1997 $1,950

Increased understanding of the immune system coupled with genetic engineering and other cutting-edge technologies, is encouraging the development of a new generation of vaccines using diverse approaches. A new round of prototype tumor vaccines is expected to advance in clinical trials in the next two to three years. Some vaccines represent a broad-based approach, attempting to trigger the whole immune system, while others are directed at specific targets. If successful, cancer vaccines will first be used therapeutically, to boost the immune response to cancer in patients already afflicted. A vaccine that would actually prevent cancer in high-risk individuals will be the next step, although this is probably years away. NEW MEDICINE has just released a cancer vaccine report providing an in-depth analysis of the cancer vaccine sector based on NEW MEDICINE’S ONCOLOGY KNOWLEDGEBASE. (see page 5). This report provides a comprehensive analysis of the cancer vaccine sector in terms of: basic science (tumorigenesis, oncogenes, tumor-suppressor genes, mitogenic growth factors and growth inhibitory factors, viral causes, apoptosis, immune response, tumor antigens, immune surveillance); technology (antiviral vaccines against cancer, nonspecific and specific active immunotherapy, whole tumor cell vaccines, gene transfer, protein antigens, adoptive immunotherapy, activated killer cells, tumor-infiltrating lymphocytes, passive immunotherapy, adjuvants); indications and epidemiology (worldwide incidence by disease severity and survival and mortality statistics for major cancers); products under development (a comprehensive database of over 160 cancer vaccines in development worldwide, including data on developer/affiliate, technology and clinical status); market opportunities worldwide (by indication based on candidate populations and suggested treatment costs); and developer profiles (over 60 companies).
Agricultural Genetics 392
Agouron Pharmaceuticals 313, 451, 482
Affymetrix 385
Aetna Health Plan 437
Aeson Therapeutics 451, 477
Advanced Therapies 506
ADAC Laboratories 340, 341
Abgenix 451, 477, 478
Limited Partnership 485
Aberlyn Capital Management
Abbott Laboratories
Aastrom Biosciences
Akorn
Alabama University
Albany Medical College
Aflacell
Allegheny-Singer Research Institute
Allergan
Allergan Ligand Retinoid Therapeutics
AltaRx
Alza
American Cyanamid
American Home Products
Amer sham International
Amira
Angelini
Antwerp University Hospital
Amen
Ammor Hospital das Clínicas
Andrus Pharmaceutical
Ansari
Anticancer
Antigenics
Antisoma
Aphion
Applied Immune Sciences (AIS)
Apollon
Apotex
Apothecon
Aquilla Biopharmaceutical
Ares Serono
Arizona Cancer Center
Arlington Cancer Center
Arnon Pharmaceuticals
Asta Medica
ATL
Atrix Laboratories
Austin Research Institute
Avigen

INDEX OF COMPANIES & INSTITUTIONS

Astrom Biosciences 451
Abbott Laboratories 303, 305, 313, 417, 523
Aberlyn Capital Management Limited Partnership 485
Abgenix 451, 477, 478
ADAC Laboratories 340, 341
Advanced Therapies 506
Aeon Therapeutics 451, 477
Aetna Health Plan 437
Affymetrix 385
Agouron Pharmaceuticals 313, 451, 482
Agricultural Genetics 392

LIST OF EXHIBITS

Patients with Prostate Cancer Treated by Drug Therapy (1995) 303
Commercially Available Drugs for the Treatment of Prostate Cancer 304
Selected Combination Chemotherapy and Multimodality Therapy in Prostate Cancer 308
Novel Drugs in Development for the Treatment of Prostate Cancer 313
Estimated Potential Annual Market for Therapeutic and Prophylactic Vaccines for Prostate Cancer 321
Estimated Potential Annual Market for Prophylactic Vaccines for Prostate Cancer Five Years Post-Introduction 322
Incidence and Mortality of Female Breast Cancer in Selected World Regions in 1995 335
Incidence of Breast Cancer in Situ in Selected World Regions in 1995 336
Probability of Developing Invasive Breast Cancer Over 10-year Time Intervals 337
Age-Specific Incidence of Female Breast Cancer in Selected World Regions 338
Estimated Incidence of Breast Cancer Cases Caused by BRCA1 Mutations and Prevalence of BRCA1 Mutations in Selected World Populations 339
Radioimmunoconjugates in Diagnostic Imaging-Approved or Filed for Approval 341
Current Concepts on the Function of the Immune System 347
Tumor Vaccine Approaches 348
Estimated Costs of Immunization Regimens 355
Potential Markets for Tumor Vaccines for Selected Cancers in North America, Europe and Japan 355
Randomized Clinical Trials in Mammography Screening 359
Estimated Mammography Procedures in Selected World Regions in 1995 360
Novel Drugs in Development for the Treatment of AIDS-Associated KS 365

Randomized Clinical Trials in Oncology 372
Patient Selection and Randomization Criteria in Oncology RCTs 375
A Comparison of Clinical Trial Research Methodologies 379
Breast Biopsies Performed in Selected World Regions in 1995 382
Recurrence and Survival Rates Based on Lymph Node Involvement 384
Agents in Development for the Treatment of Prostate Cancer 393
Infections that may Lead to Cervical Intraepithelial Neoplasia and Cervical Cancer 393
Incidence and Mortality of Cervical Cancer in Selected World Regions in 1995 405
Breast Cancer Staging and Populations by Stage 411
Estimated Stage Distribution of Female Breast Cancer at Time of Diagnosis in Selected World Regions 412
Estimated Stage Distribution of Breast Cancer by Hormonal Status at Time of Diagnosis in Selected World Regions 413
Estimated Five-Year Survival of Female Breast Cancer by Stage in Selected World Regions 414
Stage Distribution of Breast Cancer by Race in the USA at Time of Diagnosis 415
Stage Distribution and Five-Year Survival of Female Breast Cancer in the USA by Race 415
Drugs on the Market Worldwide for the Treatment of Breast Cancer 416
Treatment of Breast Cancer by Disease Stage and Hormonal Status 421
Incidence of Invasive Breast Cancer by Histologic Types at First Diagnosis in the USA 424
Estimated Surgical Procedures for Breast Cancer in Selected World Regions in 1995 425
Selected Clinical Trials of Monotherapy/Combination Therapy in the Management of Advanced/Metastatic Breast Cancer 427

1995 Estimates of Patients Treated by Chemotherapy and/or Hormonal Therapy in Selected World Regions 438
Novel Drugs in Development for the Management of Breast Cancer 451
Breast Cancer Patients on Hormonal Therapy in 1996 475
Estimated Potential Market for Prophylactic Vaccines for Breast Cancer in Selected World Regions 487
Incidence and Mortality of Ovarian Cancer in Selected World Regions in 1995 499
Types and Attributes of Oligonucleotide-based Drugs 503
Selected Oligonucleotide-based Agents in Development for the Treatment of Breast Cancer 506
Selected Ovarian Cancer Markers 516
Ovarian Cancer Incidence by Histologic Type 522
FIGO Stage for Primary Carcinoma of the Ovary at Diagnosis 524
Estimated Stage Distribution of Ovarian Cancer at Time of Diagnosis in Selected World Regions in 1995 525
Estimated Five-Year Survival of Ovarian Cancer by Stage in Selected World Regions in 1995 525
Topoisomerase I Inhibitors in Development 526
Commercially Available Topoisomerase I Inhibitors 530
Selected Irinotecan (CPT-11) Monotherapy Trial Results 533
Selected Topotecan Monotherapy Trial Results 535
Selected Topoisomerase I Inhibitor-based Combination Chemotherapy Trial Results 538

COPYRIGHT © 1997 NEW MEDICINE, INC. 714. 830. 0448.
Hematopoietic Factor Support in Oncology: Products and Market Opportunities

REPORT #402 300 PAGES SEPTEMBER 1997 $3,500

Global epidemiology by indication; historic and forecast treated/candidate populations by indication and treatment methodology (bone marrow, stem cell/ peripheral blood and cord blood transplantation); technology, products and markets; adjunct therapies; competitive assessment and company profiles.

University of North Carolina, School of Pharmacy
University of Pennsylvania Medical Center
University of Pittsburgh
University of Rochester
University of Southern California (USC)
University of Tennessee
University of Texas, Austin
University of Texas, Galveston
University of Texas Health Science Center
University of Texas Medical School
University of Texas, San Antonio
University of Texas Southwestern Medical Center
University of Toronto and Saskari
University of the Philippines
University of Toronto
University of Utah
University of Virginia
University of Washington
University of Wisconsin
UroCor
UroCor, Disease Management Information Systems
UroCor Diagnostics
UROS
UroSciences
UroTherapeutics
Vanderbilt University
Vaxcel
Ventana Medical Systems
Vical
VimRx
Vincent T. Lombardi Cancer Research Center
Virogenetics
Visible Genetics
Wadley Technologies
WadTech
Walder Reed Army Medical Center
Walther Cancer Institute
Warner-Lambert
Washington University
Wayne State University
Weizmann Institute of Science
Westminster Medical School
World Health Organization (WHO)
Wound Healing of Oklahoma
Wyeth-Ayerst
Wyeth-Ayerst Research
Wyeth-Ayerst Research
Xenova
Xenotech
Yakult Honsha
Yamanouchi
Yale University
Yeda
Zeneca
Zeneca Yakuhin KK
Zynaxis

Roerig
Royal Postgraduate Medical School
Rush-Presbyterian-St. Luke's Medical Center
Sak Institute
Sandoz
Sandton Oncology Centre
Sankyo
Sanofi
Schering AG
Sanofi Winthrop
Schering-Plough
Scientific Protein Laboratories
Scotia Holdings
Scripps Research Institute
Seaar
Sequana Therapeutics
Sequel Therapeutics
Sequans Pharmaceuticals
Ser, di Oncologia, Spedali Civili
Shergen
Sheron Laboratories
Shady Side Hospital
Sheffield Medical Technologies
Shionogi
Shire Pharmaceuticals
Sidney Kimmel Cancer Center
Sigma-Tau
Singapore General Hospital
Sloan-Kettering Institute for Cancer Research
SmithKline Beecham (SKB)
Space Telescope Science Institute
Sparta Pharmaceuticals
SRI International
SSMU (Shanghai, PRC)
St. Bartholomew's Hospital
St. Chiara Hospital
Sterilization Technical Services
Stethoscope University
Stieglitz
Stratford University
Stragene Biotechnologies
Sugen
Sumitomo
SunPharm
Sunnybrook Health Science Center
THE U.S. MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS

REPORT #202  337 PAGES  MAY 1996  $3,950

The market for radiopharmaceuticals which was $447 million in the USA in 1995, is expected to reach $1,336 million in 2002. Wider application of newer interventional modalities, such as atherectomy, vascular stents, laser angioplasty and microcatheter infusion systems for thrombolytic agents, will contribute to this growth. Among new radiopharmaceuticals currently under development, particularly promising are technetium linked peptides for imaging atherosclerosis and thrombus formation, agents for cancer detection and tumor identification, and agents for identifying infection sites of unknown origin. This report provides a comprehensive assessment of the market for radiopharmaceuticals in the USA, with insight as to new products and diagnostic techniques. It also provides data on procedure volume in all applications, with estimates of products and manufacturers’ sales volume and market share in all market segments. The report also estimates market shares of all major manufacturers by market segment and profiles 27 companies in the field.

FUTURE ONCOLOGY STAFF:

PUBLISHER AND EDITOR: Katie Siafacca, MS
ASSOCIATE EDITOR: Sarah Nghiem
EPIDEMIOLOGY: Kristina Lorenson, MPH
SCIENCE & TECHNOLOGY: Diane Etchison, PhD
CIRCULATION: Milan Sheth
DATABASE MANAGER: Richard Glenn Williams
RESEARCH: Feisal Yamani and Shaun Gray
DESIGN & PRODUCTION: Jill Burch

ORDER FORM

FUTURE ONCOLOGY (ISSN 1082-331X) is published as 10 issues (two double issues) per year, with a free annual index listing companies/institutions and subjects covered.

☐ YES, I want to order a subscription to FUTURE ONCOLOGY.

SUBSCRIPTION INFORMATION:

☐ One-year subscription to FUTURE ONCOLOGY is $720 to USA addresses and $780 overseas; please specify period (from _______ to _______)
☐ One-year subscription (V3 #1 to #12) plus all back issues (V1 #1 to V2 #12) covering a three-year period from May 1995 to April 1998 is $1,840 to USA addresses and $2,100 overseas
☐ Two-year subscription (V2 and 3, May 1996-April 1998) is $1,400 to USA addresses and $1,500 overseas
☐ Two-year back issues (V1 and 2, May 1995-April 1997) is $1,300 to USA addresses and $1,390 overseas
☐ Additional subscriptions in the same envelope are $390 each

INQUIRY INFORMATION:

☐ Please send me a sample issue of FUTURE ONCOLOGY
☐ Please send me the indexes of Volumes 1 and 2
☐ Please send me a sample profile of the ONCOLOGY DRUGS DATABASE

☐ YES, I want to order the following NEW MEDICINE reports:

<table>
<thead>
<tr>
<th>ORDER</th>
<th>INQUIRY</th>
<th>REPORT</th>
<th>TOPIC</th>
<th>RELEASE</th>
<th>PRICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>202</td>
<td>Radiopharmaceuticals</td>
<td>May 1996</td>
<td>$3,950</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
<td>401</td>
<td>Cancer Vaccines</td>
<td>June 1997</td>
<td>$1,950</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
<td>402</td>
<td>Hematopoietic Factors</td>
<td>September 1997</td>
<td>$3,500</td>
</tr>
</tbody>
</table>

All orders must be prepaid or accompanied by a signed order form or P.O. #. Subscriptions will begin upon receipt of payment. Products are nonreturnable; please, feel free to call for additional information.

My check for $ _______________ is enclosed (make checks payable to NEW MEDICINE, INC.). Payment must accompany your order; checks must be drawn on a U.S. bank.

Wire Transfer: F&M Bank, 23772 Rockfield Blvd., Lake Forest, CA 92630, (714) 855-8211, Routing #122 201 198, NEW MEDICINE INC., Account #11 71 10 51

Credit Card: ☐ Visa ☐ AmEx ☐ M/C # ☐ Exp. _______________
Bill me on P.O. # ________________________________

Signature ________________________________
Name ________________________________
Title ________________________________
Company ________________________________
Address _________________________________________________________________________________
City ________________________________ State ________________________________
Zip code ________________________________ Country ________________________________
Telephone __________________________________________ Fax ________________________________
E-Mail ________________________________

RETURN TO: NEW MEDICINE, INC.
P.O. Box 909, Lake Forest, California 92630
Tel: 714. 830. 0448  Fax: 714. 830. 0887  e-mail: newmedinc@aol.com
www:http://www.wp.com/new_med/

SALE OF FUTURE ONCOLOGY IS MADE UNDER THE FOLLOWING CONDITIONS:

Unauthorized photocopying, distribution or electronic storage is strictly prohibited. Information published in FUTURE ONCOLOGY is developed from various sources believed to be reliable. There can be no assurance that such information is accurate in all respects, however, and the publisher cannot be held liable for errors. Errors, when discovered, will be corrected. Subscriptions may not be canceled, but may be transferred.

COPYRIGHT © 1997 NEW MEDICINE, INC. 714. 830. 0448.
To date, Future Oncology has presented:

- A database of over 700 agents in development for the treatment of cancer
- Detailed incidence and mortality estimates as well as selected epidemiologic data by cancer type and stage and type of treatment, etc., for the USA, Europe, Japan and other world regions
- Current and forecast drug markets, worldwide
- Profiles of over 80 commercial programs in the oncology area
- Detailed descriptions of putative mechanisms of carcinogenesis
- In-depth discussions of product development strategies
- Attendance and coverage of over 30 meetings in the cancer and related fields